Myriad Genetics Inc (MYGN) is an American company that uses gene-based medicine to develop therapeutic and molecular diagnostic products, to discover disease genes, and to understand the role these genes and their related proteins play in the onset and progression of disease. Myriad Genetics was founded in 1992, and its headquarters are located in Salt Lake City, Utah.
Currently, Myriad Genetics has a Zacks Rank #2 (Buy), but it is subject to change following the release of the company’s latest earnings report. We have highlighted some of the key statistics from this just announced report below.
Myriad Genetics:
1. Beat earnings estimates. The company posted $0.41 EPS, surpassing our Zacks Consensus Estimate of $0.35 (this number excludes $0.04 from non-recurring items).
2. Beat revenue estimates. The company saw revenue figures of $183.5 million, beating our estimate of $178 million.
3. Posted operating income of $43.3 million and net income of $26.6 million.
4. President and CEO Mark C. Capone notes that "More importantly, we continued the excellent progress on our five-year plan to transform Myriad into a diversified global pioneer in personalized medicine. We are now beginning to see the benefits of the substantial investments the Company has made in our industry-leading pipeline and international expansion, which we believe will drive significant shareholder value over the next five years."
5. MYGN is seeing no change from its closing price of $42.32 in after hours trading after its earnings report was released.
Here’s a graph that details Myriad Genetics’ recent quarterly EPS and growth rate:
Myriad Genetics Inc. (MYGN) Recent Quarterly EPS & Growth Rate | FindTheCompany
Check back later for our full analysis on Myriad Genetics’ third quarter earnings report!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research